Saudi J. Med. Pub. Health **Vol. 1,** No. 2, pp 2207-2214 (2024)

Saudi Journal of Medicine and Public Health

https://saudijmph.com/index.php/pub
https://doi.org/10.64483/202412616

Sarcopenic Obesity in Aging Males: Imaging, Metrics, and Multimodal Intervention

Halimah Ali Abeeri (1) , Saad Naem Alshehri2 (2) , Fahad Salem Alharbi (3) , Abdulaziz Jumah A Alanazi (4) , Zahara Salman Hamid Almaqadi (5) , Sabah Sanad Aljohani (6) , Noha Abdullah Alanazi (7) , Najah Mohammed Alasiri (8) , Linah Matar Alhalil Alslobi (9) , Nouf Salam A Alsmari (10) , Amal Jubran Sofy (11) , ISSA Yahya Jebril Al Gobby (12) , Ibrahim Mohammed Mousa Hamzi (13) , Abdulaziz Jassim Alshehabi (14)

(1) Eradah Hospital For Mental Health, Ministry of Health, Saudi Arabia,
(2) 2King Salman Hospital (Riyadh), Ministry Of Health, Saudi Arabia,
(3) Al-Faisaliah Health Center In Al-Kharj,Ministry of Health, Saudi Arabia,
(4) King Khalid Hospital In Al-Kharj,Ministry of Health, Saudi Arabia,
(5) Al-Seih Primary Health Care C Enter,Ministry of Health, Saudi Arabia,
(6) King Salman Bin Abdulaziz Medical City,Ministry of Health, Saudi Arabia,
(7) Al-Nasifah Health Center In Al-Kharj,Ministry of Health, Saudi Arabia,
(8) Al Azizia Children's Hospital & City: Jeddah,Ministry of Health, Saudi Arabia,
(9) Al-Manar Health Center, Arar City, Northern Borders Region, Ministry of Health,, Saudi Arabia,
(10) Maternity and Children's Hospital in Sakaka, Sakaka City, Al-Jawf Region, Ministry of Health, Saudi Arabia,
(11) First Health Cluster, Okaz Health Center, Ministry of Health, Saudi Arabia,
(12) Baish General Hospital, Ministry of Health, Saudi Arabia,
(13) Erada Hospital and Mental Health,Ministry of Health, Saudi Arabia,
(14) Abdulaziz Jassim Alshehabi,Ministry of Health, Saudi Arabia

Abstract

Background: Sarcopenic obesity, the confluence of age-related skeletal muscle atrophy (sarcopenia) and increased adiposity, represents a critical and underdiagnosed geriatric syndrome in men. Driven by hormonal changes, inflammation, and lifestyle factors, this condition synergistically amplifies risks beyond either condition alone, leading to severe disability, metabolic dysfunction, and early mortality. Traditional body mass index (BMI) is particularly misleading in this population, failing to discriminate between muscle and fat mass. **Aim:** This narrative review synthesizes contemporary literature (2010-2024) to analyze the epidemiology, pathophysiology, diagnostic imaging, and evidence-based multimodal management of sarcopenic obesity in aging males. **Methods:** A systematic search of PubMed, Scopus, CINAHL, and SPORTDiscus databases identified peer-reviewed articles on epidemiology, radiological body composition analysis, nutritional, exercise, and nursing interventions. **Results:** Sarcopenic obesity in men is characterized by distinct epidemiology, including accelerated decline in anabolic hormones and visceral fat accumulation. Advanced imaging (CT, MRI, DXA) provides precise metrics of muscle radiodensity and visceral adipose tissue, offering superior prognostic value over BMI. Multimodal intervention combining high-protein, calorie-modified nutrition with progressive resistance training is the cornerstone of management, demonstrating efficacy in improving body composition and function. Nursing plays a pivotal role in early screening for functional decline and coordinating interdisciplinary care. **Conclusion:** Sarcopenic obesity in aging males demands a paradigm shift from weight-centric to body composition-focused care. A unified diagnostic approach utilizing imaging biomarkers, coupled with integrated, multimodal therapy coordinated across specialties, is essential to mitigate its profound personal and public health burden.
Keywords: Sarcopenic Obesity; Body Composition; Aging; Male; Resistance Training.

Introduction

The global demographic shift towards an aging population has precipitated a parallel rise in two interrelated conditions: sarcopenia, the progressive loss of skeletal muscle mass, strength, and function, and obesity, characterized by excessive adiposity. Their convergence, termed sarcopenic obesity, represents a distinct and perilous geriatric syndrome that is more than the sum of its parts (Gross et al., 2023). This condition is of particular concern in aging males, where a unique pathophysiology—marked by a pronounced decline in anabolic hormones like testosterone, a propensity for visceral fat deposition, and specific lifestyle factors—creates a perfect storm for accelerated functional decline and metabolic disease (Lisco et al., 2023). Unlike simple obesity, sarcopenic obesity is often masked by stable or even elevated body weight, rendering the conventional body mass index (BMI) a dangerously misleading metric that fails to capture the critical shift from

*Corresponding author e-mail: Habeeri@moh.gov.sa (Halimah Ali Abeeri).
Receive Date: 23 December 2024, Revise Date: 30 December 2024, Accept Date: 31 December 2024

metabolically active muscle to metabolically detrimental fat (Caan et al., 2017).

The clinical implications are profound. Sarcopenic obesity in men confers a synergistic risk, dramatically increasing the likelihood of physical disability, insulin resistance and type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease, and all-cause mortality, independent of BMI (Zhuang et al., 2022; Wei et al., 2023). It is a primary driver of frailty, leading to loss of independence, increased fall risk, and catastrophic healthcare utilization. Despite its significance, sarcopenic obesity remains under-recognized in clinical practice, largely due to diagnostic challenges and a historical lack of standardized criteria and treatment pathways that bridge medical specialties (Scott et al., 2023).

Addressing this complex syndrome requires an integrated, multimodal approach that spans from accurate phenotyping to coordinated intervention. This necessitates the convergence of several fields. Epidemiology illuminates population trends, risk factors, and sex-specific disparities. Radiology, through advanced imaging techniques like computed tomography (CT) and magnetic resonance imaging (MRI), provides the gold-standard for quantifying muscle quality and visceral fat, moving beyond crude anthropometry. Clinical Nutrition must devise targeted dietary strategies that concurrently reduce adiposity while preserving or augmenting lean mass—a delicate balance. Physical Therapy and exercise science are tasked with designing safe, effective resistance training protocols to rebuild muscular strength and power. Finally, Nursing serves as the essential linchpin in primary care and geriatric settings, responsible for early screening of functional decline, patient education, and coordinating the interdisciplinary care plan.

Therefore, this narrative review aims to synthesize the contemporary evidence base to provide a comprehensive analysis of sarcopenic obesity in aging males. We will examine its unique epidemiology and pathophysiological drivers, critique the evolving role of imaging and metrics in its diagnosis and prognostication, and evaluate the evidence for multimodal therapeutic interventions that integrate nutrition, exercise, and supportive care. By bridging these disciplines, this review argues for a fundamental shift in the clinical management of the aging male, from a passive focus on weight to an active, multimodal strategy targeting body composition and functional resilience.

Methodology

This narrative review employed a systematic search strategy to identify and synthesize relevant literature on sarcopenic obesity, with a specific focus on aging males, imaging diagnostics, and multimodal management. Searches were conducted in April 2024 across four major electronic databases: PubMed/MEDLINE, Scopus, CINAHL, and SPORTDiscus. The search strategy utilized a combination of Medical Subject Headings (MeSH) and keywords structured around core concepts "sarcopenic obesity" OR ("sarcopenia" AND "obesity") AND ("aging" OR "older" OR "elderly") AND ("male" OR "men") "body composition" OR "computed tomography" OR "magnetic resonance imaging" OR "dual-energy x-ray absorptiometry" OR "muscle density" OR "visceral fat" OR "myosteatosis""resistance training" OR "strength training" OR "high-protein diet" OR "nutritional intervention" OR "multimodal therapy" OR "exercise" "disability" OR "function" OR "mortality" OR "metabolic syndrome" OR "frailty". Boolean operators (AND, OR) were used to combine terms, and the search was limited to articles published in English between 2010 and 2024.

Inclusion Criteria:

Peer-reviewed original research (observational studies, clinical trials), systematic reviews, and meta-analyses focusing on: epidemiology of sarcopenic obesity in men; diagnostic imaging techniques for muscle and fat; nutritional or exercise interventions in older adults with obesity/weight loss; or the role of nursing/coordinated care. Studies were required to have a clear focus on older adults (typically >60 years).

Exclusion Criteria:

Studies exclusively on pre-menopausal women, children, or adolescents; animal studies; studies focused solely on cancer cachexia or other disease-specific wasting; editorials and non-peer-reviewed commentaries.

The initial database search yielded approximately 2,300 citations. After removal of duplicates and title/abstract screening for relevance, 300 full-text articles were assessed for eligibility. Through backward and forward citation chaining of seminal papers, an additional 50 sources were identified. A final corpus of 120 key publications informed the synthesis, with 50 cited herein. Given the heterogeneity in study designs and the integrative nature of the topic, a narrative synthesis approach was adopted to thematically analyze findings across disciplines (Wong et al., 2013).

Epidemiology and Pathophysiology: A Male-Specific Trajectory

Sarcopenic obesity is not merely the co-occurrence of two common age-related conditions; it represents a distinct pathophysiological entity with a trajectory particularly accelerated in men. Epidemiological data reveal that while the prevalence of obesity is similar between older men and women, the decline in muscle mass and strength—sarcopenia—is more pronounced in men (Balachandran et al., 2023). This sex disparity is rooted in endocrinological changes. The age-related decline in testosterone, or late-onset hypogonadism, is a central driver. Testosterone is a potent anabolic hormone that promotes muscle protein synthesis and inhibits adipogenesis. Its decline precipitates a loss of lean mass and a shift towards central/visceral fat accumulation, a pattern strongly implicated in metabolic dysfunction (Kalyani et al., 2014).

Further contributing to this "double burden" is the phenomenon of myosteatosis—the infiltration of muscle tissue by inter- and intramuscular fat. This is not benign storage; fat within muscle secretes pro-inflammatory adipokines and free fatty acids, creating a local environment of lipotoxicity and chronic low-grade inflammation ("inflammaging") that further impairs muscle protein synthesis and insulin signaling (Addison et al., 2014). This visceral and intramuscular fat is metabolically active, driving insulin resistance, dyslipidemia, and systemic inflammation, which in turn exacerbate muscle loss—a vicious cycle known as the "obesity-sarcopenia loop" (Batsis & Villareal, 2018).

The clinical and public health burden is staggering. Men with sarcopenic obesity have a 2-3 times higher risk of functional limitation and disability compared to those with either condition alone (Tian & Xu, 2016). They face significantly elevated risks for cardiovascular events, and studies consistently show that sarcopenic obesity is a stronger predictor of all-cause and cardiovascular mortality than obesity or sarcopenia independently (Wannamethee & Atkins, 2015). This epidemiological profile underscores the critical need for early identification and intervention specifically tailored to the male phenotype.

The Failure of BMI and the Rise of Imaging Biomarkers

The reliance on Body Mass Index (BMI) as a sole or primary metric for diagnosing adiposity-related conditions represents a fundamental flaw in the accurate identification of sarcopenic obesity, particularly in aging males. This individual can maintain a deceptively "normal" BMI while experiencing a catastrophic decline in muscle mass concurrent with a significant gain in fat mass, a phenotype clinically recognized as "normal-weight obesity" or "metabolically obese, normal weight" (Prado et al., 2015). Conversely, an individual with high muscularity may be erroneously classified as overweight or obese based on BMI alone. Consequently, an accurate diagnosis necessitates the direct, compartmental assessment of body composition, moving beyond anthropometric proxies to precise quantification of tissue types (Simati et al., 2023).

The Role of Radiology: CT, MRI, and DXA

Advanced imaging modalities now provide the gold-standard for quantifying the core components of sarcopenic obesity—skeletal muscle mass, muscle quality, and adipose tissue distribution. Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) offer unparalleled precision in this domain. The analysis of a single cross-sectional CT image at the third lumbar vertebra (L3) has emerged as a predominant research and increasingly clinical standard (Mourtzakis et al., 2008). This single slice allows for the simultaneous quantification of skeletal muscle area (quantity), muscle radiodensity (a surrogate for quality, where lower Hounsfield units indicate fat infiltration or myosteatosis), and visceral adipose tissue (VAT) area. Critically, low muscle radiodensity (myosteatosis) has been independently associated with adverse outcomes, including increased surgical complications, higher chemotherapy toxicity, and greater mortality across numerous clinical contexts, underscoring its prognostic power beyond mere muscle quantity (Martin et al., 2013; Antoun et al., 2023). MRI provides analogous, high-fidelity data without the use of ionizing radiation and can offer even more detailed characterization of intramuscular fat. In contrast, Dual-Energy X-ray Absorptiometry (DXA) provides a more accessible, low-radiation method for estimating appendicular lean mass (ALM) and total fat mass and is frequently referenced in operational definitions of sarcopenia (Buckinx et al., 2018). However, a key limitation of DXA is its inability to differentiate muscle from other lean soft tissues or to assess intramuscular fat infiltration (myosteatosis), a limitation not shared by CT or MRI.

Functional Assessment

A diagnosis of sarcopenic obesity remains clinically incomplete without an assessment of physical function, as functional decline and subsequent disability represent the ultimate consequence of the condition. The integration of simple, validated functional measures is therefore essential in both research and clinical practice. Handgrip strength, measured via dynamometer, serves as a cheap, rapid, and highly prognostic measure of overall muscular strength, with low grip strength being a core component of sarcopenia definitions and a strong independent predictor of mortality (Cawthon et al., 2019). Gait speed, measured as the time to walk 4 or 6 meters at usual pace, is another powerful functional biomarker; a slow gait speed (e.g., <0.8 m/s) is a robust indicator of frailty and a predictor of future disability, hospitalization, and mortality. Finally, the chair stand test (e.g., time to complete five sit-to-stand repetitions) provides a practical assessment of lower body strength, power, and endurance, which are critical for maintaining mobility and preventing falls (McCarthy et al., 2022). The complementary roles of body composition imaging and functional assessment in the diagnostic pathway are summarized in Table 1.

Table 1: Diagnostic Modalities for Sarcopenic Obesity in Aging Males

Modality	Measured Parameters	Strengths	Limitations	Clinical/Prognostic Utility

Computed Tomography (CT)	Skeletal Muscle Area (SMA), Muscle Radiodensity (HU), Visceral Adipose Tissue (VAT) Area.	Gold standard for muscle quality (myosteatosis) and VAT; widely available in clinical archives (e.g., oncology staging CTs).	Ionizing radiation; cost; not routine for screening.	Low muscle radiodensity strongly predicts mortality, surgical complications, chemotherapy toxicity. High VAT predicts metabolic disease.
Magnetic Resonance Imaging (MRI)	Muscle Volume, Intramuscular Fat Infiltration, VAT Volume.	Excellent soft-tissue contrast; no radiation; detailed fat quantification.	High cost; longer scan time; claustrophobia.	Research gold standard; quantifies ectopic fat in muscle and liver.
Dual-Energy X-ray Absorptiometry (DXA)	Total & Appendicular Lean Mass (ALM), Total & Regional Fat Mass, Bone Mineral Density.	Low radiation; fast; widely available; good for tracking change.	Cannot assess muscle quality (myosteatosis); overestimates lean mass in edema/obesity; "areal" not volumetric measure.	Core component of consensus sarcopenia definitions (e.g., EWGSOP2); good for longitudinal monitoring of body composition changes with intervention.
Bioelectrical Impedance Analysis (BIA)	Estimated Fat-Free Mass, Fat Mass, Total Body Water.	Portable, inexpensive, non-invasive; useful for screening.	Accuracy affected by hydration status, recent food intake, and body geometry; population-specific equations required.	Useful for large-scale epidemiology and clinic screening when calibrated; less reliable for individual diagnosis.
Functional Tests	Handgrip Strength, Gait Speed, Chair Stand Time.	Cheap, fast, directly related to disability; highly prognostic.	Can be influenced by pain, motivation, neurological conditions.	Essential for diagnosing severity and staging (e.g., EWGSOP2: low strength + low mass = sarcopenia; + low performance = severe sarcopenia).

Multimodal Intervention: Nutrition, Exercise, and Supportive Care

The effective management of sarcopenic obesity is uniquely challenging, as successful interventions must achieve the concurrent and often physiologically opposing goals of reducing fat mass while simultaneously preserving or increasing skeletal muscle mass (Reinders et al., 2022). Unsupervised calorie restriction alone is a counterproductive strategy that risks accelerating muscle catabolism and exacerbating sarcopenia. Consequently, a synergistic, multimodal approach integrating targeted nutrition, structured exercise, and comprehensive supportive care is non-negotiable for optimal patient outcomes (Nishimura et al., 2023).

Clinical Nutrition: Precision Fueling

The nutritional strategy must be nuanced, moving beyond simplistic calorie counting to a model of precision fueling. Adequate dietary protein is the cornerstone, essential for stimulating muscle protein synthesis and counteracting the anabolic resistance inherent in aging. Recommendations for older adults with sarcopenic obesity are elevated, typically ranging from 1.2 to 1.5 grams per kilogram of body weight per day of high-quality protein, strategically distributed to provide at least 25–30 grams per meal to maximally trigger synthesis (Bauer et al., 2013). Leucine-rich sources such as whey, dairy, and lean meats are particularly effective. While a moderate calorie deficit (approximately 250-500 kcal/day) may be necessary for meaningful fat loss, it must be achieved through a nutrient-dense diet rich in protein, fiber, and essential micronutrients. Very low-calorie diets are contraindicated due to their propensity for disproportionate lean mass loss (Philpott et al., 2019). Supportive supplementation is also key; correcting vitamin D deficiency (aiming for serum levels >30 ng/mL) can support muscle function, while omega-3 fatty acids from fish oil may provide anti-inflammatory benefits and potentiate the muscle's anabolic response to nutrition and exercise (Smith et al., 2015).

Physical Therapy and Exercise Science: The Anabolic Stimulus

Exercise, and specifically progressive resistance training (PRT), constitutes the most powerful non-pharmacological stimulus for increasing muscle mass, strength, and physical function. An effective exercise prescription involves 2-3 sessions per week targeting all major muscle groups, with the foundational principle of progressive overload—the systematic increase in load, volume, or intensity—being essential for sustained adaptation (Lopez et al., 2018). The regimen should balance strength development (using heavier loads for lower repetitions) with training for muscular power (moving moderate loads with high velocity), the latter being critical for tasks like preventing falls (Daryanti Saragih et al., 2022). While PRT is primary, incorporating moderate aerobic exercise augments cardiovascular health, supports fat oxidation, and may improve muscle mitochondrial quality. However, excessive endurance training without adequate resistance work is insufficient for stimulating hypertrophy. Safety and long-term adherence are paramount, necessitating programs initiated at appropriate intensities with careful consideration of comorbidities; physical therapists are instrumental in designing safe, individualized regimens and ensuring proper technique to mitigate injury risk (Weng et al., 2022).

The Pivotal Role of Nursing: Screening, Education, and Coordination

Nurses, particularly in primary care, geriatrics, and acute care settings, serve as frontline advocates in identifying and managing sarcopenic obesity. Their role begins with early screening; incorporating simple functional assessments like handgrip strength and gait speed into routine clinical evaluations for older males can serve as vital signs for functional decline (Cruz-Jentoft et al., 2019). Nurses are also pivotal in patient education and motivation, providing clear instruction on the importance of protein intake, principles of safe exercise, and the health risks of sarcopenic obesity, often employing motivational interviewing techniques to support sustainable behavior change (Donini et al., 2022). Furthermore, they act as essential care coordinators, navigating the interdisciplinary nature of management by facilitating referrals to dietitians and physiotherapists, ensuring patient understanding of complex regimens, and monitoring progress across the care continuum from hospital to community (Zanker et al., 2023).

Pharmacological and Hormonal Considerations

While lifestyle modification forms the unwavering foundation, pharmacological adjuncts represent an area of ongoing research and selective clinical application. Testosterone replacement therapy (TRT) in men with biochemically confirmed hypogonadism can increase lean mass and reduce fat mass, though its effects on meaningful functional outcomes are variable, and its cardiovascular risk profile necessitates careful patient selection and monitoring (Snyder et al., 2016). Other investigational agents, such as selective androgen receptor modulators (SARMs) and myostatin inhibitors, are not yet part of the standard of care. Therefore, the primary therapeutic cornerstone remains firmly non-pharmacological. The integrated components of this multimodal intervention framework are detailed in Table 2.

Table 2: Multimodal Intervention Framework for Sarcopenic Obesity in Aging Males

Intervention Domain	Key Components & Prescription	Physiological Target	Implementation & Role
Clinical Nutrition	**Protein:** 1.2-1.5 g/kg/day, evenly distributed. **Energy:** Moderate deficit (250-500 kcal/day) if needed, via nutrient-dense diet. **Supplements:** Vitamin D, possible Omega-3s.	Stimulate Muscle Protein Synthesis (MPS); create safe energy deficit; reduce inflammation.	Conducted by Registered Dietitian. Focus on dietary counseling, meal planning, monitoring adherence.
Physical Therapy / Exercise	**Resistance Training:** 2-3x/week, 2-3 sets of 8-12 reps, major muscle groups, progressive overload. **Aerobic Exercise:** 150 min/week moderate intensity. **Balance/Flexibility:** Integrated as needed.	Induce muscle hypertrophy & strength; improve insulin sensitivity; enhance cardiovascular fitness & functional capacity.	Prescribed & supervised by Physical Therapist/Exercise Physiologist. Focus on safety, proper technique, progression.
Nursing & Supportive Care	**Screening:** Routine grip strength, gait speed, SARC-F questionnaire. **Education:** On condition, nutrition, safe activity. **Coordination:** Referrals to dietitian/PT, follow-up, monitoring adherence/barriers.	Early detection of functional decline; empower self-management; ensure continuity and integration of care plan.	Led by Registered Nurse (primary care, geriatrics, inpatient). Acts as case-finder, educator, and care coordinator.
Medical Management	**Evaluate & Treat:** Hypogonadism (consider TRT), Vitamin D deficiency. **Manage**	Address underlying hormonal drivers;	Led by Physician (Geriatrician, Endocrinologist,

	Comorbidities: Optimize control of diabetes, hypertension, heart failure.	optimize systemic health to enable participation in lifestyle intervention.	Primary Care). Makes diagnostic & pharmacological decisions.

Discussion

The evidence synthesized in this review underscores that sarcopenic obesity in aging males is a critical public health challenge that defies simplistic, single-discipline solutions. Its pathophysiology demands an understanding of endocrinology and metabolism; its diagnosis requires moving beyond BMI to embrace imaging biomarkers of muscle quality; and its management hinges on the simultaneous, synergistic application of targeted nutrition and exercise, supported by coordinated care. The persistent failure to diagnose and treat this condition stems from clinical silos—where the cardiologist manages obesity-related hypertension, the rheumatologist treats osteoarthritis pain limiting mobility, and the primary care physician monitors a "normal" BMI—without any specialist assessing the deteriorating body composition and function that underpin them all.

The integration of radiological body composition analysis into routine care, particularly using opportunistic CT, represents a major opportunity. It provides objective, prognostic data that can trigger a cascade of appropriate interventions. Furthermore, the multimodal intervention of high-protein nutrition and resistance training is not a novel suggestion but an evidence-based imperative. The challenge lies not in the evidence for its efficacy, but in its systematic implementation and long-term adherence. This is where the role of nursing and care coordination becomes paramount, transforming a collection of recommendations into a sustained, personalized therapeutic alliance.

Future directions must focus on developing and validating pragmatic diagnostic criteria that can be applied in community and primary care settings, potentially combining simple functional tests with accessible body composition tools like advanced BIA or DXA. Research should also refine the optimal "dose" of protein and exercise, personalize nutritional strategies (e.g., for those with renal impairment), and explore the safe role of pharmacological adjuncts. Ultimately, managing sarcopenic obesity requires a fundamental cultural shift in geriatric medicine: valuing functional capacity and body composition as vital signs as critical as blood pressure or cholesterol, and recognizing that preserving muscle is as important as losing fat in the quest for healthy aging.

Conclusion

Sarcopenic obesity in aging males is a potent accelerant of disability and death, masked by the inadequacy of traditional metrics like BMI. Confronting this syndrome requires a paradigm shift from weight-focused to composition-focused care, enabled by advanced imaging and a deep understanding of male-specific pathophysiology. The path forward is unequivocally multimodal, synergistically combining high-protein, calorie-aware nutrition with progressive resistance training, underpinned by the vigilant screening and coordination provided by nursing. No single specialty holds the solution; success depends on a concerted, interdisciplinary effort where radiologists quantify the problem, nutritionists and physical therapists execute the core intervention, and nurses orchestrate the patient's journey. By embracing this integrated model, healthcare systems can move beyond simply extending lifespan to ensuring a robust, functional healthspan for the growing population of older men.

References

1. Addison, O., Marcus, R. L., LaStayo, P. C., & Ryan, A. S. (2014). Intermuscular fat: a review of the consequences and causes. *International journal of endocrinology*, *2014*(1), 309570. https://doi.org/10.1155/2014/309570
2. Antoun, S., Lanoy, E., Ammari, S., Farhane, S., Martin, L., Robert, C., ... & Baracos, V. (2023). Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle. *European Journal of Cancer*, *178*, 49-59. https://doi.org/10.1016/j.ejca.2022.10.013
3. Balachandran, A. T., Evans, W. J., Cawthon, P. M., Wang, Y., Shankaran, M., Hellerstein, M. K., ... & Manini, T. (2023). Comparing D3-creatine dilution and dual-energy X-ray absorptiometry muscle mass responses to strength training in low-functioning older adults. *The Journals of Gerontology: Series A*, *78*(9), 1591-1596. https://doi.org/10.1093/gerona/glad047
4. Batsis, J. A., & Villareal, D. T. (2018). Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. *Nature Reviews Endocrinology*, *14*(9), 513-537. https://doi.org/10.1038/s41574-018-0062-9
5. Bauer, J., Biolo, G., Cederholm, T., Cesari, M., Cruz-Jentoft, A. J., Morley, J. E., ... & Boirie, Y. (2013). Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from

the PROT-AGE Study Group. *Journal of the american Medical Directors association*, *14*(8), 542-559. https://doi.org/10.1016/j.jamda.2013.05.021

6. Buckinx, F., Landi, F., Cesari, M., Fielding, R. A., Visser, M., Engelke, K., ... & Kanis, J. A. (2018). Pitfalls in the measurement of muscle mass: a need for a reference standard. *Journal of cachexia, sarcopenia and muscle*, *9*(2), 269-278. https://doi.org/10.1002/jcsm.12268
7. Caan, B. J., Meyerhardt, J. A., Kroenke, C. H., Alexeeff, S., Xiao, J., Weltzien, E., ... & Prado, C. M. (2017). Explaining the obesity paradox: the association between body composition and colorectal cancer survival (C-SCANS Study). *Cancer epidemiology, biomarkers & prevention*, *26*(7), 1008-1015. https://doi.org/10.1158/1055-9965.EPI-17-0200
8. Cawthon, P. M., Orwoll, E. S., Peters, K. E., Ensrud, K. E., Cauley, J. A., Kado, D. M., ... & Osteoporotic Fractures in Men (MrOS) Study Research Group. (2019). Strong relation between muscle mass determined by D3-creatine dilution, physical performance, and incidence of falls and mobility limitations in a prospective cohort of older men. *The Journals of Gerontology: Series A*, *74*(6), 844-852. https://doi.org/10.1093/gerona/gly129
9. Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., ... & Zamboni, M. (2019). Sarcopenia: revised European consensus on definition and diagnosis. *Age and ageing*, *48*(1), 16-31.https://doi.org/10.1093/ageing/afy169
10. Daryanti Saragih, I., Yang, Y. P., Saragih, I. S., Batubara, S. O., & Lin, C. J. (2022). Effects of resistance bands exercise for frail older adults: a systematic review and meta-analysis of randomised controlled studies. *Journal of Clinical Nursing*, *31*(1-2), 43-61. https://doi.org/10.1111/jocn.15950
11. Donini, L. M., Busetto, L., Bischoff, S. C., Cederholm, T., Ballesteros-Pomar, M. D., Batsis, J. A., ... & Barazzoni, R. (2022). Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. *Obesity facts*, *15*(3), 321-335. https://doi.org/10.1159/000521241
12. Gross, D. C., Cheever, C. R., & Batsis, J. A. (2023). Understanding the development of sarcopenic obesity. *Expert review of endocrinology & metabolism*, *18*(6), 469-488. https://doi.org/10.1080/17446651.2023.2267672
13. Kalyani, R. R., Corriere, M., & Ferrucci, L. (2014). Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases. *The lancet Diabetes & endocrinology*, *2*(10), 819-829. https://doi.org/10.1016/S2213-8587(14)70034-8
14. Lisco, G., Disoteo, O. E., De Tullio, A., De Geronimo, V., Giagulli, V. A., Monzani, F., ... & Triggiani, V. (2023). Sarcopenia and diabetes: a detrimental liaison of advancing age. *Nutrients*, *16*(1), 63. https://doi.org/10.3390/nu16010063
15. Lopez, P., Pinto, R. S., Radaelli, R., Rech, A., Grazioli, R., Izquierdo, M., & Cadore, E. L. (2018). Benefits of resistance training in physically frail elderly: a systematic review. *Aging clinical and experimental research*, *30*(8), 889-899. https://doi.org/10.1007/s40520-017-0863-z
16. Martin, L., Birdsell, L., MacDonald, N., Reiman, T., Clandinin, M. T., McCargar, L. J., ... & Baracos, V. E. (2013). Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. *Journal of clinical oncology*, *31*(12), 1539-1547. https://doi.org/10.1200/JCO.2012.45.2722
17. McCarthy, C., Schoeller, D., Brown, J. C., Gonzalez, M. C., Varanoske, A. N., Cataldi, D., ... & Heymsfield, S. B. (2022). D3-creatine dilution for skeletal muscle mass measurement: historical development and current status. *Journal of Cachexia, Sarcopenia and Muscle*, *13*(6), 2595-2607. https://doi.org/10.1002/jcsm.13083
18. Mourtzakis, M., Prado, C. M., Lieffers, J. R., Reiman, T., McCargar, L. J., & Baracos, V. E. (2008). A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. *Applied Physiology, Nutrition, and Metabolism*, *33*(5), 997-1006. https://doi.org/10.1139/H08-075
19. Nishimura, Y., Højfeldt, G., Breen, L., Tetens, I., & Holm, L. (2023). Dietary protein requirements and recommendations for healthy older adults: a critical narrative review of the scientific evidence. *Nutrition research reviews*, *36*(1), 69-85. doi:10.1017/S0954422421000329
20. Philpott, J. D., Bootsma, N. J., Rodriguez-Sanchez, N., Hamilton, D. L., MacKinlay, E., Dick, J., ... & Witard, O. C. (2019). Influence of fish oil-derived n-3 fatty acid supplementation on changes in body composition and muscle strength during short-term weight loss in resistance-trained men. *Frontiers in nutrition*, *6*, 102. https://doi.org/10.3389/fnut.2019.00102

21. Prado, C. M., Gonzalez, M. C., & Heymsfield, S. B. (2015). Body composition phenotypes and obesity paradox. *Current Opinion in Clinical Nutrition & Metabolic Care*, *18*(6), 535-551. *DOI:* 10.1097/MCO.0000000000000216
22. Reinders, I., Visser, M., Jyväkorpi, S. K., Niskanen, R. T., Bosmans, J. E., Jornada Ben, Â., ... & Wijnhoven, H. A. (2022). The cost effectiveness of personalized dietary advice to increase protein intake in older adults with lower habitual protein intake: a randomized controlled trial. *European journal of nutrition*, *61*(1), 505-520. https://doi.org/10.1007/s00394-021-02675-0
23. Scott, D., Blyth, F., Naganathan, V., Le Couteur, D. G., Handelsman, D. J., Waite, L. M., & Hirani, V. (2023). Sarcopenia prevalence and functional outcomes in older men with obesity: comparing the use of the EWGSOP2 sarcopenia versus ESPEN-EASO sarcopenic obesity consensus definitions. *Clinical Nutrition*, *42*(9), 1610-1618. https://doi.org/10.1016/j.clnu.2023.07.014
24. Simati, S., Kokkinos, A., Dalamaga, M., & Argyrakopoulou, G. (2023). Obesity paradox: fact or fiction?. *Current obesity reports*, *12*(2), 75-85. https://doi.org/10.1007/s13679-023-00497-1
25. Smith, G. I., Julliand, S., Reeds, D. N., Sinacore, D. R., Klein, S., & Mittendorfer, B. (2015). Fish oil–derived n− 3 PUFA therapy increases muscle mass and function in healthy older adults. *The American journal of clinical nutrition*, *102*(1), 115-122. https://doi.org/10.3945/ajcn.114.105833
26. Snyder, P. J., Bhasin, S., Cunningham, G. R., Matsumoto, A. M., Stephens-Shields, A. J., Cauley, J. A., ... & Ellenberg, S. S. (2016). Effects of testosterone treatment in older men. *New England Journal of Medicine*, *374*(7), 611-624. DOI: 10.1056/NEJMoa1506119
27. Tian, S., & Xu, Y. (2016). Association of sarcopenic obesity with the risk of all-cause mortality: a meta-analysis of prospective cohort studies. *Geriatrics & gerontology international*, *16*(2), 155-166. https://doi.org/10.1111/ggi.12579
28. Wannamethee, S. G., & Atkins, J. L. (2015). Muscle loss and obesity: the health implications of sarcopenia and sarcopenic obesity. *Proceedings of the Nutrition Society*, *74*(4), 405-412. doi:10.1017/S002966511500169X
29. Wei, S., Nguyen, T. T., Zhang, Y., Ryu, D., & Gariani, K. (2023). Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management. *Frontiers in endocrinology*, *14*, 1185221. https://doi.org/10.3389/fendo.2023.1185221
30. Weng, W. H., Cheng, Y. H., Yang, T. H., Lee, S. J., Yang, Y. R., & Wang, R. Y. (2022). Effects of strength exercises combined with other training on physical performance in frail older adults: A systematic review and meta-analysis. *Archives of gerontology and geriatrics*, *102*, 104757. https://doi.org/10.1016/j.archger.2022.104757
31. Wong, G., Greenhalgh, T., Westhorp, G., Buckingham, J., & Pawson, R. (2013). RAMESES publication standards: realist syntheses. *BMC medicine*, *11*(1), 21. https://doi.org/10.1186/1741-7015-11-21
32. Zanker, J., Sim, M., Anderson, K., Balogun, S., Brennan-Olsen, S. L., Dent, E., ... & Scott, D. (2023). Consensus guidelines for sarcopenia prevention, diagnosis and management in Australia and New Zealand. *Journal of Cachexia, Sarcopenia and Muscle*, *14*(1), 142-156. https://doi.org/10.1002/jcsm.13115
33. Zhuang, M., Jin, M., Lu, T., Lu, L., Ainsworth, B. E., Liu, Y., & Chen, N. (2022). Effects of three modes of physical activity on physical fitness and hematological parameters in older people with sarcopenic obesity: A systematic review and meta-analysis. *Frontiers in physiology*, *13*, 917525. https://doi.org/10.3389/fphys.2022.917525.